Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGES AZZI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1265743017
CMS profile
1401680
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$24,246.25

260 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Adaptive Biotechnologies Corporation $9,480.34 9
Astellas Pharma US Inc $4,559.46 8
AstraZeneca Pharmaceuticals LP $1,936.90 13
Astellas Pharma Global Development $1,856.74 2
Novartis Pharmaceuticals Corporation $1,307.08 27
Tempus AI, Inc $1,174.27 12
PFIZER INC. $547.25 30
Merck Sharp & Dohme LLC $364.95 16
Janssen Biotech, Inc. $330.76 17
PUMA BIOTECHNOLOGY, INC. $215.31 6
Takeda Pharmaceuticals U.S.A., Inc. $174.82 10
GlaxoSmithKline, LLC. $170.22 9
Celgene Corporation $162.80 9
E.R. Squibb & Sons, L.L.C. $157.99 9
ARRAY BIOPHARMA INC $127.03 5
Eisai Inc. $124.62 6
Lilly USA, LLC $119.02 5
ABBVIE INC. $115.82 5
Genentech USA, Inc. $102.67 5
RECORDATI_RARE_DISEASES_INC. $92.70 4
Daiichi Sankyo Inc. $90.04 4
Alexion Pharmaceuticals, Inc. $84.53 4
Legend Biotech USA Inc. $59.40 2
Rigel Pharmaceuticals, Inc. $57.18 2
TerSera Therapeutics LLC $53.78 2
EMD Serono, Inc. $50.25 3
Deciphera Pharmaceuticals Inc. $47.89 2
Mirati Therapeutics, Inc. $44.49 2
Janssen Pharmaceuticals, Inc $43.43 4
TAIHO ONCOLOGY, INC. $43.39 2
PharmaEssentia USA Corporation $42.93 2
Bayer Healthcare Pharmaceuticals Inc. $42.57 2
Gilead Sciences, Inc. $40.16 2
Incyte Corporation $39.47 2
Blue Earth Diagnostics Limited $38.24 2
Exelixis Inc. $37.81 2
JAZZ PHARMACEUTICALS INC. $34.84 2
Ipsen Biopharmaceuticals, Inc $33.44 1
Sumitomo Pharma America, Inc. $29.55 1
Karyopharm Therapeutics Inc. $27.11 1
Acrotech Biopharma Inc. $26.71 1
Kyowa Kirin, Inc. $22.41 1
Boehringer Ingelheim Pharmaceuticals, Inc. $22.22 1
SUN PHARMACEUTICAL INDUSTRIES INC. $21.74 1
GENZYME CORPORATION $20.61 1
Fennec Pharmaceuticals, Inc. $20.20 1
ADC Therapeutics America, Inc. $17.39 1
Pharmacosmos Therapeutics Inc. $17.29 1
Genmab U.S., Inc. $16.43 1

Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGES AZZI

NPI 1265743017 · CMS profile ID 1401680

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

260 matching records · $24,246.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 260 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–260 of 260.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $83.3301/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086631187 CMS
E.R. Squibb & Sons, L.L.C. $10.9401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101225969 CMS
E.R. Squibb & Sons, L.L.C. $3.9101/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101225971 CMS
PFIZER INC. $35.1201/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131128957 CMS
Alexion Pharmaceuticals, Inc. $18.2001/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093985392 CMS
PFIZER INC. $7.7001/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131108094 CMS
GlaxoSmithKline, LLC. $2.0001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116491967 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144953101 CMS
TAIHO ONCOLOGY, INC. $18.3401/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137934595 CMS
ABBVIE INC. $33.4001/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103258439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,609.46 92
PY2020 $629.57 29
PY2021 $11,747.27 139
PY2022 $9,962.63 153
PY2023 $46,457.05 219
PY2024 $24,246.25 260
PY2025 $16,323.45 231

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,366,306.64 121
PY2024 Principal investigator $226,847.53 14
PY2023 Principal investigator $160,151.62 35
PY2022 Principal investigator $146,187.26 26
PY2021 Principal investigator $68,185.02 12
PY2020 Principal investigator $76,614.00 8
PY2019 Principal investigator $9,730.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

121 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577676
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $75,198.00 11/05/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807015
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,795.00 11/05/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807017
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150,628.20 11/05/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807019
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 11/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577670
Principal investigator 1 Boehringer Ingelheim Espana S.A. $20.98 11/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577672
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577674
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $511,630.33 10/31/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996258
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40,853.70 10/09/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807013
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577668
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $388,839.05 09/30/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996260
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346972
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346974
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346976
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346978
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346980
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346982
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346984
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346986
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346988
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346990
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346992
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346994
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346996
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223346998
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347000
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347002
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347004
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347006
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347008
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347010
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347012
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347014
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347016
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347018
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347020
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347022
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347024
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347026
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347028
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347030
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347032
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347034
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347036
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347038
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347040
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347042
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347044
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347046
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347048
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347050
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347052
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347054
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347056
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347058
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347060
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347062
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347064
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347066
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347068
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347070
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347072
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347074
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347076
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347078
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347080
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347082
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347084
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347086
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347088
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347090
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347092
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347094
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347096
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347098
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347100
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347102
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347104
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347106
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347108
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347110
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347112
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347114
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347116
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347118
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347120
Principal investigator 1 Daiichi Sankyo Inc. $55.08 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347122
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347124
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347126
Principal investigator 1 Daiichi Sankyo Inc. $30.24 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347128
Principal investigator 1 Daiichi Sankyo Inc. $17.79 09/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347130
Principal investigator 1 Daiichi Sankyo Inc. $945.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347132
Principal investigator 1 Daiichi Sankyo Inc. $370.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-793 No dispute reported 06/30/2026 1223347134
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577666
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577660
Principal investigator 1 Boehringer Ingelheim Espana S.A. $20.98 08/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577662
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 08/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577664
Principal investigator 1 Janssen Research & Development, LLC $250.00 07/17/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175391863
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 07/10/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O No dispute reported 06/30/2026 1175391875
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577658
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577656
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $87.90 05/27/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996254
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $34.98 05/27/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996256
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/19/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175391869
Principal investigator 1 Mirati Therapeutics, Inc. $1,537.77 05/16/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530061
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577652
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577654
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,753.00 04/23/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31,086.90 04/22/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220807009
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577646
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 04/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577648
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 04/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577650
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $117.20 03/25/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996246
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $163.24 03/25/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996248
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 03/25/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996250
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10.64 03/25/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996252
Principal investigator 1 PFIZER INC. $750.00 03/14/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228863079
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577642
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577640
Principal investigator 1 AstraZeneca Pharmaceuticals LP $134,179.45 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185538621
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
Holy Cross Health Heart And Vascular Care
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577644